|
EP3202410B1
(en)
|
2010-04-14 |
2020-03-25 |
Roger Williams Medical Center |
Methods and compositions for treating hiv
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
AU2012207356A1
(en)
*
|
2011-01-18 |
2013-08-01 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
CA3133545C
(en)
|
2012-05-25 |
2023-08-08 |
Cellectis |
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
|
|
US9365641B2
(en)
|
2012-10-01 |
2016-06-14 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting stromal cells for the treatment of cancer
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
ES2824024T3
(es)
|
2012-10-10 |
2021-05-11 |
Sangamo Therapeutics Inc |
Compuestos modificadores de células T y usos de los mismos
|
|
US20150320799A1
(en)
|
2012-12-20 |
2015-11-12 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
LT2956175T
(lt)
|
2013-02-15 |
2017-12-11 |
The Regents Of The University Of California |
Chimerinis antigeno receptorius ir jo panaudojimo būdai
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
|
CN105518018B
(zh)
|
2013-03-15 |
2020-04-03 |
细胞基因公司 |
修饰的t淋巴细胞
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
RS65484B1
(sr)
|
2013-05-13 |
2024-05-31 |
Cellectis |
Cd19 specifični himerni antigenski receptor i njegove primene
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
CA2924668A1
(en)
*
|
2013-09-23 |
2015-03-26 |
Wilson Wolf Manufacturing Corporation |
Improved methods of genetically modifying animal cells
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
AU2014368383B2
(en)
|
2013-12-20 |
2020-01-16 |
Cellectis |
Method of engineering multi-input signal sensitive T cell for immunotherapy
|
|
ES2963718T3
(es)
|
2014-01-21 |
2024-04-01 |
Novartis Ag |
Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras
|
|
KR102375998B1
(ko)
*
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
FI3888674T3
(fi)
|
2014-04-07 |
2024-07-02 |
Novartis Ag |
Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria
|
|
SG11201608393TA
(en)
*
|
2014-04-10 |
2016-11-29 |
Seattle Children S Hospital Dba Seattle Children S Res Inst |
Transgene genetic tags and methods of use
|
|
KR20160145802A
(ko)
*
|
2014-04-23 |
2016-12-20 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
|
|
SI3689899T1
(sl)
|
2014-04-25 |
2022-01-31 |
2Seventy Bio, Inc. |
MND promotor kimeričnih antigenskih receptorjev
|
|
EP3738597A1
(en)
|
2014-04-25 |
2020-11-18 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
EP4008725A1
(en)
|
2014-05-02 |
2022-06-08 |
The Trustees of the University of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor t cells
|
|
NZ726989A
(en)
*
|
2014-06-06 |
2020-08-28 |
Bluebird Bio Inc |
Improved t cell compositions
|
|
WO2016014565A2
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
BR112017001242A2
(pt)
|
2014-07-21 |
2017-12-05 |
Novartis Ag |
tratamento de câncer usando um receptor antigênico quimérico a cd33
|
|
SG10201900455YA
(en)
|
2014-07-24 |
2019-02-27 |
Bluebird Bio Inc |
Bcma chimeric antigen receptors
|
|
RU2017102769A
(ru)
*
|
2014-07-29 |
2018-08-28 |
Пфайзер Инк. |
EGFRvIII СПЕЦИФИЧЕСКИЕ ХИМЕРНЫЕ АНТИГЕННЫЕ РЕЦЕПТОРЫ ДЛЯ ИММУНОТЕРАПИИ РАКА
|
|
MY189028A
(en)
|
2014-08-19 |
2022-01-20 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
EP3186284B1
(en)
|
2014-08-28 |
2022-04-06 |
BioAtla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
CA2961636A1
(en)
|
2014-09-17 |
2016-03-24 |
Boris ENGELS |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CN106973568B
(zh)
|
2014-10-08 |
2021-07-23 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
|
MA40318A
(fr)
*
|
2014-11-05 |
2017-09-13 |
Juno Therapeutics Inc |
Procédés de transduction et de traitement de cellules
|
|
NZ733025A
(en)
|
2014-12-12 |
2022-01-28 |
2Seventy Bio Inc |
Bcma chimeric antigen receptors
|
|
KR20170090506A
(ko)
|
2014-12-19 |
2017-08-07 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
IL303247A
(en)
|
2014-12-29 |
2023-07-01 |
Novartis Ag |
Methods for preparing cells expressing a chimeric receptor antigen
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
CA2973529A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
WO2016126608A1
(en)
*
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
KR102624023B1
(ko)
|
2015-02-24 |
2024-01-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
결합-촉발된 전사 스위치 및 이들의 이용 방법
|
|
BR112017020750A2
(pt)
|
2015-03-27 |
2018-06-26 |
Harvard College |
células t modificadas e métodos de produção e utilização das mesmas
|
|
IL254817B2
(en)
|
2015-04-08 |
2023-12-01 |
Novartis Ag |
Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
|
|
CN108473957B
(zh)
|
2015-04-17 |
2024-07-16 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
KR20180002795A
(ko)
*
|
2015-05-13 |
2018-01-08 |
칼리뮨, 인코포레이티드 |
렌티바이러스 벡터의 바이오-생산
|
|
KR20180029201A
(ko)
|
2015-05-18 |
2018-03-20 |
티씨알2 테라퓨틱스 인크. |
융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법
|
|
BR112017025166A2
(en)
|
2015-05-28 |
2018-07-31 |
Kite Pharma, Inc. |
Methods of Conditioning Patients for T-Cell Therapy
|
|
KR20230148387A
(ko)
|
2015-05-28 |
2023-10-24 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위한 진단 방법
|
|
JP2018521069A
(ja)
*
|
2015-07-16 |
2018-08-02 |
プロスペクト チャーターケア アールダブリュエムシー，エルエルシー ディ／ビー／エイ ロジャー ウィリアムズ メディカル センターＰｒｏｓｐｅｃｔ Ｃｈａｒｔｅｒｃａｒｅ Ｒｗｍｃ，Ｌｌｃ Ｄ／Ｂ／Ａ Ｒｏｇｅｒ Ｗｉｌｌｉａｍｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ |
腹膜癌を治療するための組成物及び方法
|
|
JP7146632B2
(ja)
|
2015-07-21 |
2022-10-04 |
ノバルティス アーゲー |
免疫細胞の有効性および増大を改善する方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US11458167B2
(en)
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
IL292504B2
(en)
|
2015-10-20 |
2024-01-01 |
Kite Pharma Inc |
Methods of preparing T cells for T cell therapy
|
|
CN114231486A
(zh)
*
|
2015-10-30 |
2022-03-25 |
儿童国家医疗中心 |
从未致敏t细胞群体产生hpv抗原特异性t细胞
|
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
CA3005125A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Novartis Ag |
Buffers for stabilization of lentiviral preparations
|
|
WO2017087723A1
(en)
*
|
2015-11-19 |
2017-05-26 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
WO2017088012A1
(en)
|
2015-11-27 |
2017-06-01 |
Cartherics Pty. Ltd. |
Genetically modified cells and uses thereof
|
|
JP2018536436A
(ja)
|
2015-12-04 |
2018-12-13 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
MA44140A
(fr)
|
2015-12-22 |
2021-05-19 |
Dana Farber Cancer Inst Inc |
Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
|
|
EA201891589A1
(ru)
|
2016-01-08 |
2019-01-31 |
Те Риджентс Оф Те Юниверсити Оф Калифорния |
Условно активные гетеродимерные полипептиды и способы их применения
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
PE20190356A1
(es)
|
2016-04-01 |
2019-03-07 |
Kite Pharma Inc |
Receptores quimericos y metodos de uso de los mismos
|
|
PL3436079T3
(pl)
|
2016-04-01 |
2021-12-20 |
Kite Pharma, Inc. |
Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
|
|
US10689450B2
(en)
|
2016-04-01 |
2020-06-23 |
Kite Pharma, Inc |
BCMA binding molecules and methods of use thereof
|
|
JP7282521B2
(ja)
|
2016-04-08 |
2023-05-29 |
パーデュー・リサーチ・ファウンデイション |
Ｃａｒ ｔ細胞療法のための方法および組成物
|
|
WO2017180587A2
(en)
|
2016-04-11 |
2017-10-19 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
WO2018018958A1
(en)
|
2016-04-22 |
2018-02-01 |
Carsgen Therapeutics Co., Ltd. |
Compositions and methods of cellular immunotherapy
|
|
WO2017186121A1
(zh)
*
|
2016-04-26 |
2017-11-02 |
科济生物医药（上海）有限公司 |
一种改善免疫应答细胞功能的方法
|
|
JP7051715B2
(ja)
|
2016-05-13 |
2022-04-11 |
バイオアトラ、エルエルシー |
抗Ｒｏｒ２抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用
|
|
JP7373991B2
(ja)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
US11077178B2
(en)
|
2016-09-21 |
2021-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (CAR) that targets chemokine receptor CCR4 and its use
|
|
IL302917A
(en)
|
2016-10-07 |
2023-07-01 |
Tcr2 Therapeutics Inc |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
ES2916335T3
(es)
|
2016-10-20 |
2022-06-30 |
Celgene Corp |
Receptores de antígeno quimérico heterodimerizable basados en cereblon
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
JP7291396B2
(ja)
|
2016-11-22 |
2023-06-15 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
TWI785009B
(zh)
|
2017-02-14 |
2022-12-01 |
美商凱特製藥公司 |
Ｃｄ７０結合分子及使用彼之方法
|
|
WO2018160622A1
(en)
|
2017-02-28 |
2018-09-07 |
Endocyte, Inc. |
Compositions and methods for car t cell therapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
CN110809581A
(zh)
|
2017-03-16 |
2020-02-18 |
高山免疫科学股份有限公司 |
Pd-l2变体免疫调节蛋白及其用途
|
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
LT3596116T
(lt)
|
2017-03-16 |
2023-11-10 |
Alpine Immune Sciences, Inc. |
Imunomoduliacinių baltymų pd-l1 variantai ir jų naudojimo būdai
|
|
MX2019011272A
(es)
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Composiciones y metodos para inmunooncologia.
|
|
SG11201908784TA
(en)
*
|
2017-03-27 |
2019-10-30 |
Hoffmann La Roche |
Improved antigen binding receptor formats
|
|
ES2954311T3
(es)
|
2017-04-01 |
2023-11-21 |
Avm Biotechnology Llc |
Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
|
|
CN110494158A
(zh)
|
2017-04-03 |
2019-11-22 |
凯德药业股份有限公司 |
使用包含优化的多功能t细胞的嵌合受体t细胞进行治疗
|
|
CN110753555A
(zh)
|
2017-04-19 |
2020-02-04 |
得克萨斯州大学系统董事会 |
表达工程化抗原受体的免疫细胞
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
SG10202112528QA
(en)
|
2017-05-12 |
2021-12-30 |
Jackson Lab |
Nsg mice lacking mhc class i and class ii
|
|
JP7657023B2
(ja)
|
2017-06-09 |
2025-04-04 |
プロビデンス ヘルス アンド サービシーズ－オレゴン |
がんの処置のための腫瘍反応性ヒトｔ細胞の同定のためのｃｄ３９およびｃｄ１０３の使用
|
|
JP2020530277A
(ja)
|
2017-06-30 |
2020-10-22 |
セレクティスＣｅｌｌｅｃｔｉｓ |
反復投与のための細胞免疫療法
|
|
CA3070579A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
WO2019055896A1
(en)
*
|
2017-09-15 |
2019-03-21 |
Kite Pharma, Inc. |
METHODS AND SYSTEMS FOR PERFORMING A PATIENT-CLEAN IMMUNOTHERAPY PROCEDURE WITH FOLLOW-UP OF BIOLOGICAL SAMPLE CHAIN OF CONTROL AND IDENTITY CHAIN
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
KR20230007557A
(ko)
|
2017-09-22 |
2023-01-12 |
카이트 파마 인코포레이티드 |
키메라 폴리펩티드 및 그의 용도
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
CA3084470A1
(en)
|
2017-10-18 |
2019-04-25 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
BR112020007576A2
(pt)
|
2017-10-18 |
2020-09-24 |
Novartis Ag |
composições e métodos para degradação de proteína seletiva
|
|
MX2020004540A
(es)
|
2017-10-18 |
2020-08-03 |
Alpine Immune Sciences Inc |
Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
|
|
KR20250143360A
(ko)
|
2017-11-10 |
2025-10-01 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
종양 항원을 타겟으로 하는 키메릭 항원 수용체
|
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
EP3735417A1
(en)
|
2018-01-03 |
2020-11-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12491153B2
(en)
|
2018-01-03 |
2025-12-09 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
EP3740285A1
(en)
|
2018-01-15 |
2020-11-25 |
Pfizer Inc. |
Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist
|
|
AU2019209432A1
(en)
|
2018-01-22 |
2020-08-06 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Methods of use for CAR T cells
|
|
WO2019161271A1
(en)
|
2018-02-16 |
2019-08-22 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
|
EP3755349A4
(en)
|
2018-02-21 |
2021-11-17 |
Board of Regents, The University of Texas System |
PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
|
|
WO2019165237A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
AU2019231205A1
(en)
|
2018-03-06 |
2020-09-24 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
CN115925952A
(zh)
|
2018-03-13 |
2023-04-07 |
东莞凡恩世生物医药有限公司 |
抗叶酸受体1抗体及其用途
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
WO2019200325A1
(en)
|
2018-04-12 |
2019-10-17 |
Kite Pharma, Inc. |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
EP3801572B1
(en)
|
2018-06-01 |
2024-07-03 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
EP3801642A4
(en)
|
2018-06-05 |
2022-03-23 |
The Trustees of The University of Pennsylvania |
COMPOSITIONS AND METHODS FOR CHIMERIC AUTOANTIBODY RECEPTOR CELLS OF MUSCLE-SPECIFIC KINASE
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
AU2019284911A1
(en)
|
2018-06-13 |
2020-12-17 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
US20210269501A1
(en)
*
|
2018-06-25 |
2021-09-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
TWI865456B
(zh)
*
|
2018-07-09 |
2024-12-11 |
大陸商沐特圖公司 |
葉酸受體阿法特異性抗體
|
|
KR20210038922A
(ko)
|
2018-08-02 |
2021-04-08 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 요법 t 세포 확장 동역학 및 그의 용도
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
CA3113539A1
(en)
*
|
2018-10-10 |
2020-04-16 |
Zymeworks Inc. |
Antibody constructs binding 4-1bb and tumor-associated antigens and uses thereof
|
|
CN111197032A
(zh)
*
|
2018-11-16 |
2020-05-26 |
上海斯丹赛生物技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
US20220000921A1
(en)
*
|
2018-11-20 |
2022-01-06 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified Cell Expressing Therapeutic Agent and Uses thereof
|
|
WO2020113098A1
(en)
|
2018-11-29 |
2020-06-04 |
Vineti Inc. |
Centralized and decentralized individualized medicine platform
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
IL283734B2
(en)
|
2018-12-12 |
2025-03-01 |
Kite Pharma Inc |
Chimeric antigen receptors and CAR-T cells and methods of use
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
TW202042824A
(zh)
*
|
2019-03-27 |
2020-12-01 |
賓夕法尼亞大學董事會 |
Tn-MUC1嵌合抗原受體（CAR）T細胞療法
|
|
TW202108150A
(zh)
|
2019-05-03 |
2021-03-01 |
美商凱特製藥公司 |
投與嵌合抗原受體免疫療法之方法
|
|
WO2020231999A1
(en)
*
|
2019-05-13 |
2020-11-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells
|
|
EP3973072A1
(en)
|
2019-05-23 |
2022-03-30 |
Vogelsang, Matjaz |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
EP3983538A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
BR112021025735A2
(pt)
|
2019-06-21 |
2022-03-08 |
Kite Pharma Inc |
Receptores de tgf-ss e métodos de uso
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
CA3147441A1
(en)
|
2019-09-03 |
2021-03-11 |
Allogene Therapeutics, Inc. |
Methods of preparing t cells for t cell therapy
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
CA3154280A1
(en)
|
2019-10-11 |
2021-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
|
|
CN114981441A
(zh)
*
|
2019-10-16 |
2022-08-30 |
优莫佳生物制药股份有限公司 |
用于通用受体疗法的逆转录病毒载体
|
|
CA3163104A1
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
CN114945382A
(zh)
|
2019-11-26 |
2022-08-26 |
诺华股份有限公司 |
Cd19和cd22嵌合抗原受体及其用途
|
|
WO2021123832A1
(en)
|
2019-12-20 |
2021-06-24 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
IL299886A
(en)
|
2020-07-17 |
2023-03-01 |
Instil Bio Uk Ltd |
Receptors that provide targeted costimulation for host cell therapy
|
|
KR20230084470A
(ko)
|
2020-08-14 |
2023-06-13 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
|
CN116157868A
(zh)
*
|
2020-08-18 |
2023-05-23 |
德尔菲诊断公司 |
用于游离dna片段大小密度以评估癌症的方法和系统
|
|
US12152251B2
(en)
|
2020-08-25 |
2024-11-26 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
JP2023542539A
(ja)
|
2020-09-24 |
2023-10-10 |
ザ ジャクソン ラボラトリー |
免疫細胞療法を評価するためのヒト化マウスモデル
|
|
EP4263600A1
(en)
|
2020-12-18 |
2023-10-25 |
Century Therapeutics, Inc. |
Chimeric antigen receptor systems with adaptable receptor specificity
|
|
IL303984A
(en)
|
2020-12-24 |
2023-08-01 |
Kite Pharma Inc |
Chimeric antigen receptors for prostate cancer
|
|
CA3207182A1
(en)
|
2021-01-10 |
2022-07-14 |
Kite Pharma, Inc. |
T cell therapy
|
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
|
US12454563B2
(en)
|
2021-03-11 |
2025-10-28 |
Kite Pharma, Inc. |
Immune cell function
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
JP7688723B2
(ja)
|
2021-04-16 |
2025-06-04 |
カイト ファーマ インコーポレイテッド |
Ｔａｃｉ／ｂｃｍａ二重結合分子
|
|
AR125461A1
(es)
|
2021-04-27 |
2023-07-19 |
Takeda Pharmaceuticals Co |
Células presentadoras de antígeno recombinante
|
|
US12357646B2
(en)
|
2021-05-14 |
2025-07-15 |
Kite Pharma, Inc. |
Chimeric antigen receptor T cell therapy
|
|
JP2024521756A
(ja)
|
2021-05-24 |
2024-06-04 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体
|
|
CA3218590A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
CN117730100A
(zh)
|
2021-06-08 |
2024-03-19 |
凯德药业股份有限公司 |
Gpc3结合分子
|
|
EP4355340A4
(en)
|
2021-06-16 |
2025-05-21 |
Instil Bio, Inc. |
RECEPTORS FOR TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY
|
|
US20230027004A1
(en)
|
2021-07-01 |
2023-01-26 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
JP2024525485A
(ja)
|
2021-07-02 |
2024-07-12 |
カイト ファーマ インコーポレイテッド |
細胞療法適用において使用される遺伝子構築物由来の遺伝子産物におけるバリアントを特定するための方法
|
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
US20250108113A1
(en)
|
2021-12-30 |
2025-04-03 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
EP4463549A2
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
EP4463548A1
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
AU2023221839A1
(en)
|
2022-02-15 |
2024-08-22 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy.
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
KR20250017239A
(ko)
|
2022-06-09 |
2025-02-04 |
카이트 파마 인코포레이티드 |
세포 치료를 위한 림프구 제조 방법
|
|
CN119816590A
(zh)
|
2022-08-10 |
2025-04-11 |
武田药品工业株式会社 |
低免疫原性的经修饰细胞
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
TW202530421A
(zh)
|
2022-10-28 |
2025-08-01 |
美商凱特製藥公司 |
用於將免疫療法最佳化之因素
|
|
CN119997962A
(zh)
|
2022-10-28 |
2025-05-13 |
凯德药业股份有限公司 |
改善免疫疗法的功效和持久应答
|
|
US20240309428A1
(en)
|
2023-03-17 |
2024-09-19 |
Kite Pharma, Inc. |
Impact of tumor microenvironment on efficacy of immunotherapy
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
TW202506996A
(zh)
|
2023-04-27 |
2025-02-16 |
日商武田藥品工業股份有限公司 |
擴增ｃｄ５６＋／ｃｄ３－細胞之方法
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025096517A1
(en)
|
2023-11-01 |
2025-05-08 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
US20250290154A1
(en)
|
2024-03-04 |
2025-09-18 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|